Published 7 years ago on the ERC organization's page
The Big Picture
♦ ERC has a unique patented cell-based immunotherapy approach which treats tumours by directly stimulating the patient’s immune system, using whole cells and lysates of autologous (from the patient him/herself) and allogeneic tumour cells (from other patients).
♦ This therapeutic technology has been patented at the international level under the reference PCT/EP2007/050807 (WO/2007/085648).
♦ The vaccine has shown breakthrough performance on compassionate patients suffering from aggressive brain tumours (Glioblastoma Multiforme - GBM). Several patients have shown a regression of the tumour and some, a total disappearance.
♦ Our product outperforms any known standard medical treatment.